Pathological Response Prediction to Neo-adjuvant Chemoradiotherapy in Esophageal Carcinoma and Comparison of Engineered Features Versus Deep Learning Models
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 入组人数
- 150
- 试验地点
- 2
- 主要终点
- Develop models to predict pCR based on pre-neoadjuvant imaging modalities
研究概览
简要总结
In esophageal carcinoma, neoadjuvant concurrent chemo-radiotherapy (NA-CCRT) followed by surgery is the current standard of care and ample evidence has accumulated supporting the view that complete pathological response (pCR) is a positive prognostic marker for improved outcomes. Predicting the probability of achieving pCR prior to neoadjuvant treatment could permit modification of treatment protocols for those patients unlikely to achieve pCR.
Radiomics is a new entrant in the field of imaging where specific features are derived from the intensity and distribution pattern of pixels based on a region-of-interest (ROI). The features thus extracted can then be used for prediction modelling similar to other -omics datasets. Preliminary investigations examining its utility have been performed and its applications have thus far focused on screening and survival prediction after treatment. Due to the multi-dimensional nature of data extracted using radiomics, Artificial Intelligence (AI) methods are ideally suited for analysing and modelling radiomic features.
Machine Learning (ML) and Deep Learning (DL)[utilising Convolutional Neural Networks (CNN)] are both part of the AI framework. In contrast to ML, DL is a new entrant and has been utilised by some medical researchers for modelling using prediction-type algorithms. Besides significantly reducing the workflow associated with Radiomics-based research, feature engineering and modelling using DL are immune to the effects of incorrect ROI delineation. However, the main limitation of DL is the 'blackbox' effect, in which the underlying basis of a CNN is not known. This has been mitigated in part by the visualisation of activation maps directly on the image dataset to prove biological plausibility of predictions. The comparative performance of both types of modelling is also not known.
Our objective is to investigate pCR probability in our study population using radiomics-based ML and AI-based modelling. We will also investigate the comparative performance of both modelling techniques. For DL based prediction modelling, we will attempt to provide biological plausibility on the basis of activation maps.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •ECOG Performance Status: 0-2
- •Patients with histopathological or cytopathological confirmed malignancy of the esophagus
- •Histology: Squamous Cell Carcinoma and Adenocarcinoma
- •Patients should have received NeoAdjuvant Concurrent Chemoradiation (NACCRT) followed by Surgery
- •All therapeutic interventions (Radiotherapy, Chemotherapy & Surgery) delivered within participating institutions
- •At least one pre-NACCRT DICOM imaging dataset (HRCT/ 18-FDG PET-CT/ Radiotherapy planning CT) for each patient
排除标准
- •Patients with any metallic implants in the region of interest
- •Patient with locally advanced disease or metastatic disease (T4 disease, Fistula, metastases)
- •Patients with prior history of radiotherapy in the same region
- •Patients developing a second malignancy in the esophagus
研究组 & 干预措施
Study Group
Patients undergoing NA-CCRT followed by Surgery
干预措施: Neo-Adjuvant Radiotherapy (Radiation)
Study Group
Patients undergoing NA-CCRT followed by Surgery
干预措施: Neo-Adjuvant Chemotherapy (Drug)
Study Group
Patients undergoing NA-CCRT followed by Surgery
干预措施: Esophagectomy (Procedure)
结局指标
主要结局
Develop models to predict pCR based on pre-neoadjuvant imaging modalities
时间窗: August 2021
Perform a clinical audit of patient outcomes (OS, RFS, pCR rate) after new-adjuvant chemoradiation and esophagectomy
时间窗: January 2020
次要结局
未报告次要终点
研究者
Dr Kundan Singh Chufal
Senior Consultant & Chief of Thoracic Radiation Oncology, Department of Radiation Oncology
Rajiv Gandhi Cancer Institute & Research Center, India
